Neue Therapieoptionen bei fortgeschrittenen Schilddrüsenkarzinomen

Schlüsselwörter

Schilddrüsenkarzinom - Multityrosinkinase-Inhibitoren - Sorafenib - Sunitinib - Vandetanib

Keywords

thyroid cancer - multi-tyrosine kinase inhibitors - sorafenib - sunitinib - vandetanib

Literatur

• 1 Bible K C, Suman V J, Molina J R. et al . Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers.  Lancet Oncol. 2010;  11 962-972
• 2 Carr L L, Mankoff D A, Goulart B H. et al . Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.  Clin Cancer Res. 2010;  16 5260-5268
• 3 Cohen E EW, Needles B M, Cullen K J. et al . Phase 2 study of sunitinib in refractory thyroid cancer.  J Clin Oncol. 2008;  26 (Suppl.) Abstract 6025
• 4 Cohen E EW, Rosen L S, Vokes E E. et al . Axitinib is an active traetment for all histologic subtypes of advanced thyroid cancer.  J Clin Oncol. 2008;  26 4708-4713
• 5 De Souza J A, Busaidy N, Zimrin A. et al . Phase II trial of sunitinib in medullary thyroid cancer (MTC).  J Clin Oncol. 2010;  28 (Suppl.) Abstract 5504
• 6 Gupta-Abramson V, Troxel A B, Nellore A. et al . Phase II trial of sorafenib in advanced thyroid cancer.  J Clin Oncol. 2008;  26 4714-4719
• 7 Hoftijzer H, Heemastra K A, Morreau H. et al . Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.  Eur J Endocrinol. 2009;  161 923-931
• 8 Kloos R T, Ringel M D, Knopp M V. et al . Phase II trial of sorafenib in metastatic thyroid cancer.  J Clin Oncol. 2009;  27 1675-1684
• 9 Kurzrock R, Cohen E E, Sherman S I. et al . Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL 184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.  J Clin Oncol. 2010;  28 (Suppl.) Abstract 5502
• 10 Lam E T, Ringel M D, Kloos R T. et al . Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.  J Clin Oncol. 2010;  28 2323-2330
• 11 Ravaud A, de la Fouchardiere C, Courbon F. et al . Sunitinib in patients with refractory advanced thyroid cancer.  J Clin Oncol. 2008;  26 Suppl Abstract 6058
• 12 Robinson B G, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.  J Clin Endocrinol Metab. 2010;  95 2664-2671
• 13 Schlumberger M, Elisei R, Bastholt L. et al . Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.  J Clin Oncol. 2009;  27 3794-3801
• 14 Sherman S I, Wirth L J, Droz J -P. et al . Motesanib diphosphate in progressive differentiated thyroid cancer.  New Engl J Med. 2008;  359 31-42
• 15 Wells S A, Gosnell J E, Gagel R F. et al . Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.  J Clin Oncol. 2010;  28 767-772
• 16 Wells S A, Robinson B G, Gagel R F. et al . Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC).  J Clin Oncol. 2010;  28 (Suppl.) Abstract 5503
• 17 Woyach J A, Shah M H. New therapeutic advances in the management of progressive thyroid cancer.  Endocrine Rel Cancer. 2009;  16 715-731